Showing 3971-3980 of 4926 results for "".
- Suneva Grows Their Aesthetics Portfolio with New Dealshttps://practicaldermatology.com/news/suneva-grows-their-aesthetics-portfolio-with-new-deals/2459946/Suneva® Medical, Inc., is partnering with Healeon Medical, Inc and Puregraft, LLC to add two new products to their a
- Dermavant Sciences Appoints Dr. Philip M. Brown as Chief Medical Officerhttps://practicaldermatology.com/news/dermavant-sciences-appoints-dr-philip-m-brown-as-chief-medical-officer/2459949/Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, appointed Philip M. Brown, MD, JD, as Chief Medical Officer. With more than 25 years of experience leading clinical development programs, Dr. Brown most recently served as head of global pharmaceutical drug development at G
- Modernizing Medicine Introduces New Patient Engagement Toolshttps://practicaldermatology.com/news/modernizing-medicine-introduces-new-patient-engagement-tools/2459951/Modernizing Medicine has launched enhanced patient engagement tools powered by Relatient that are designed to reduce no-shows and improve patient compliance, satisfaction, and operational efficiency. Patients who do not show for appointments can be a significant cost and ef
- National Rosacea Society: New Grants Available in 2019https://practicaldermatology.com/news/national-rosacea-society-new-grants-available-in-2019/2457536/The National Rosacea Society (NRS) has new grants available in 2019 to support research into potential causes and other key aspects of rosacea that may lead to improvements in its management, prevention, or potential cure. The deadline for submitting proposals for research grants in 2019 is
- Almirall and X-Chem Team Up to Develop Oral Compounds for Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-and-x-chem-team-up-to-develop-oral-compounds-for-dermatological-diseases/2457545/Almirall, S.A. signed a collaborative research and license agreement with the X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases, a strategic area for Almirall. X-Chem, Inc. is a privately held biotechnology company focused on applying its indus
- Dermatologists Need More Info About Cannabinoidshttps://practicaldermatology.com/news/dermatologists-need-more-info-about-cannabinoids/2457549/Dermatologists are interested in learning more about cannabinoids and recommending them to patients, according to a new survey in Journal of Drugs in Dermatology. However, many are concerned about th
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track
- Naked Eye, Smart Phone Apps May Miss Melanomashttps://practicaldermatology.com/news/naked-eye-smart-phone-apps-may-miss-melanomas/2457486/The naked eye alone is not enough to accurately diagnosis skin cancer and smart phone apps may also miss melanomas, according to a new review published in The Cochrane Library as part of a Special Collection of Coch
- Phase 3 Data Positive for Revance's RT002https://practicaldermatology.com/news/phase-3-data-positive-for-revances-rt002/2457489/Long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term safety study. Completion of this study paves the way for Revance Therapeutics, Inc. to subm
- Encore Dermatology Announces Phase 2 Safety Data for Impoyzhttps://practicaldermatology.com/news/encore-dermatology-announces-phase-2-safety-data-for-impoyz/2457496/A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temov